Posted by Adam Dyson on Nov 8th, 2018 // No Comments
Los Angeles Capital Management & Equity Research Inc. grew its position in DexCom, Inc. (NASDAQ:DXCM) by 5.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 213,848 shares of the medical device company’s stock after acquiring an additional 11,390 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned 0.24% of DexCom worth $30,589,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of DXCM. Dimensional Fund Advisors LP raised its stake in shares of DexCom by 16.7% in the first quarter. Dimensional Fund Advisors LP now owns 148,342 shares of the medical device company’s stock valued at $11,001,000 after acquiring an additional 21,271 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of DexCom by 7.9% in the first quarter. Principal Financial Group Inc. now owns 33,469 shares of the medical device company’s stock valued at $2,482,000 after acquiring an additional 2,459 shares during the last quarter. UBS Group AG raised its stake in shares of DexCom by 76.3% in the first quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after acquiring an additional 6,890 shares during the last quarter. Clinton Group Inc. bought a new position in shares of DexCom in the second quarter valued at approximately $201,000. Finally, State of Alaska Department of Revenue raised its stake in shares of DexCom by 32.3% in the second quarter. State of Alaska Department of Revenue now owns 10,410 shares of the medical device company’s stock valued at $988,000 after acquiring an additional 2,540 shares during the last quarter. Get DexCom alerts:
A number of research firms have recently issued reports on DXCM. JPMorgan Chase & Co. lifted their target price on shares of DexCom to $140.00 and gave the company an “overweight” rating in a research note on Thursday, August 2nd. Cowen lifted their target price on shares of DexCom from $110.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, August 2nd. Oppenheimer set a $125.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Thursday, August 2nd. Jefferies Financial Group raised their price target on shares of DexCom to $148.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Piper Jaffray Companies raised their price target on shares of DexCom to $157.00 and gave the company an “overweight” rating in a report on Wednesday. Eight research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $132.50. Shares of DexCom stock opened at $144.65 on Thursday. The company has a market capitalization of $11.74 billion, a P/E ratio of -249.40 and a beta of 0.60. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. DexCom, Inc. has a fifty-two week low of $48.90 and a fifty-two week high of $148.56.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.29. The business had revenue of $266.70 million for the quarter, compared to analyst estimates of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 3.08%. The business’s quarterly revenue was up 44.5% on a year-over-year basis. Equities analysts predict that DexCom, Inc. will post -0.49 earnings per share for the current fiscal year.
In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of DexCom stock in a transaction dated Wednesday, October 10th. The shares were sold at an average price of $122.20, for a total value of $48,880.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link . Also, CEO Kevin R. Sayer sold 11,161 shares of DexCom stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $123.22, for a total transaction of $1,375,258.42. The disclosure for this sale can be found here . In the last ninety days, insiders sold 170,392 shares of company stock worth $23,416,280. Insiders own 1.80% of the company’s stock. TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Bought by Los Angeles Capital Management & Equity Research Inc.” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.wkrb13.com/2018/11/08/dexcom-inc-dxcm-shares-bought-by-los-angeles-capital-management-equity-research-inc.html.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: What is Cost of Debt?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM). Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter .
